Education
About Us
Working with TipRanks
Follow Us
Aytu BioScience Inc (AYTU)
NASDAQ:AYTU
AYTU Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.95 - $2.82
Previous CloseN/A
Volume5.78K
Average Volume (3M)239.80K
Market Cap
$18.54M
Enterprise Value$6.79M
Total Cash (Recent Filing)$18.17M
Total Debt (Recent Filing)$1.86M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Nov 17, 2025EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.93
Shares Outstanding9,911,913
10 Day Avg. Volume514,086
30 Day Avg. Volume239,801
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.72
Price to Sales (P/S)0.21
P/FCF Ratio-6.32
Enterprise Value/Market Cap0.37
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit0.14
Enterprise Value/Ebitda2.15
Forecast
1Y Price Target
$9.17Price Target Upside390.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Market PotentialEXXUA aims to become an important treatment option for the 21 million Americans affected by MDD.
Product LaunchThe company is on track for the commercial launch of EXXUA in Q4 2025.
Bears Say
Financial PerformanceAytu reported F4Q25 results with total revenue of $15.1M, which was below both consensus and estimates, leading to a decrease in stock value.
Revenue DeclineThe ADHD segment, Aytu's primary source of revenue, experienced a decline and missed sales estimates due to various factors impacting the business.
Aytu BioScience News
AYTU FAQ
What was Aytu BioScience Inc’s price range in the past 12 months?
Aytu BioScience Inc lowest stock price was $0.95 and its highest was $2.82 in the past 12 months.
What is Aytu BioScience Inc’s market cap?
Aytu BioScience Inc’s market cap is $18.54M.
When is Aytu BioScience Inc’s upcoming earnings report date?
Aytu BioScience Inc’s upcoming earnings report date is Nov 17, 2025 which is in 45 days.
How were Aytu BioScience Inc’s earnings last quarter?
Aytu BioScience Inc released its earnings results on Sep 23, 2025. The company reported -$2.93 earnings per share for the quarter, missing the consensus estimate of -$0.033 by -$2.897.
Is Aytu BioScience Inc overvalued?
According to Wall Street analysts Aytu BioScience Inc’s price is currently Undervalued.
Does Aytu BioScience Inc pay dividends?
Aytu BioScience Inc does not currently pay dividends.
What is Aytu BioScience Inc’s EPS estimate?
Aytu BioScience Inc’s EPS estimate is -0.19.
How many shares outstanding does Aytu BioScience Inc have?
Aytu BioScience Inc has 9,911,913 shares outstanding.
What happened to Aytu BioScience Inc’s price movement after its last earnings report?
Aytu BioScience Inc reported an EPS of -$2.93 in its last earnings report, missing expectations of -$0.033. Following the earnings report the stock price went down -17.928%.
Which hedge fund is a major shareholder of Aytu BioScience Inc?
Currently, no hedge funds are holding shares in AYTU
Company Description
Aytu BioScience Inc
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
AYTU Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant enthusiasm around the upcoming launch of ExuA and positive financial metrics like the third consecutive year of positive adjusted EBITDA. However, challenges such as a decline in gross margin and potential competition in the ADHD portfolio present concerns.View all AYTU earnings summariesAYTU Stock 12 Month Forecast
Average Price Target
$9.17
▲(390.37% Upside)
Technical Analysis
Ownership Overview
4.15% Insiders
4.22% Mutual Funds
50.99% Other Institutional Investors
39.49% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---